BRAF inhibitor therapy, due to paradoxical activation of the MAPK pathway (RAS-RAF-MEK-ERK), can lead to the development of melanomas and new nevi. • Patients with BRAF-mutated metastatic colorectal cancer may benefit from combined BRAF and MEK inhibitor therapy. • A pretreatment dermatologic evaluation is recommended for all patients. • Patients at high risk for melanoma (eg, positive family history, Fitzpatrick skin phototype I-II, or presence of atypical nevi) may benefit from a preventive surgical approach.
Therapy-Induced Metastatic Melanoma During Treatment With Encorafenib and Cetuximab for BRAF-Mutated Colorectal Cancer: A Case Report and Short Literature Review
Ghidini M.
2025-01-01
Abstract
BRAF inhibitor therapy, due to paradoxical activation of the MAPK pathway (RAS-RAF-MEK-ERK), can lead to the development of melanomas and new nevi. • Patients with BRAF-mutated metastatic colorectal cancer may benefit from combined BRAF and MEK inhibitor therapy. • A pretreatment dermatologic evaluation is recommended for all patients. • Patients at high risk for melanoma (eg, positive family history, Fitzpatrick skin phototype I-II, or presence of atypical nevi) may benefit from a preventive surgical approach.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S1533002825000866-main.pdf
non disponibili
Tipologia:
Versione Editoriale (PDF)
Licenza:
Copyright dell'editore
Dimensione
1.14 MB
Formato
Adobe PDF
|
1.14 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
